Curis stock (US2312691006): cancer drug setback keeps investors on edge

Curis faces renewed uncertainty after the FDA kept a partial clinical hold on its leukemia candidate, while the stock trades near multi-year lows. What US investors should know about the biotech’s pipeline, cash position and recent milestones.

Curis stock has been trading under pressure in 2026 as the oncology-focused biotech continues to work through a partial clinical hold from the US Food and Drug Administration (FDA) on its lead leukemia program and digests mixed data updates from earlier studies, according to a company filing published on 03/12/2026 and recent trading data from Nasdaq as of early May 2026, as reported by Curis investor relations as of 03/12/2026 and Nasdaq as of 05/10/2026.

As of: 17.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Curis
• Sector/industry: Biotechnology, oncology
• Headquarters/country: Lexington, Massachusetts, United States
• Core markets: US and global oncology drug development
• Key revenue drivers: Royalties from Erivedge, pipeline collaboration income, milestone payments
• Home exchange/listing venue: Nasdaq (ticker: CRIS)
• Trading currency: US dollar (USD)

Curis: core business model

Curis is a clinical-stage biotechnology company focused on developing small-molecule therapies for the treatment of cancer, with a particular emphasis on genetically defined tumors and hematologic malignancies. The company does not yet market its own internally developed products but receives royalty revenue from Erivedge, a hedgehog pathway inhibitor for advanced basal cell carcinoma that was originally developed in collaboration with Genentech and marketed by Roche, as described in its annual report for 2024 filed on 03/12/2025 with the SEC and summarized by Curis annual report summary as of 03/12/2025.

The company’s strategy revolves around advancing a portfolio of targeted cancer therapies through early and mid-stage clinical trials while relying on partnerships and capital markets to finance development. Key pipeline programs have included emavusertib, an IRAK4 inhibitor being studied in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and additional molecules aimed at epigenetic regulators or immune modulators. This focus places Curis among a group of smaller US biotech firms seeking to carve out niches in precise molecular segments of oncology, where successful proof-of-concept data can support licensing deals or future commercial launches, according to pipeline descriptions in a company presentation dated 03/18/2025 referenced by Curis corporate presentation as of 03/18/2025.

Curis generates limited recurring revenue relative to its research and development expenses, which means the business model is highly dependent on investor confidence and access to external funding. This structure is typical for development-stage biotech companies in the US market, where equity offerings, warrants and potential royalty streams often play a key role in financing multi-year clinical programs. For US investors, the investment case generally hinges more on clinical milestones, regulatory interactions and partnership dynamics than on near-term earnings metrics, as highlighted in the 2024 Form 10-K filed with the SEC on 03/12/2025 and discussed by SEC filing overview as of 03/12/2025.

Main revenue and product drivers for Curis

The primary source of current revenue for Curis is a royalty stream from Erivedge sales, which are reported by its partner and then passed through on a percentage basis to Curis. Erivedge is indicated for certain forms of advanced basal cell carcinoma, and while it is an established product, it faces competitive pressures and maturing demand dynamics. As a result, Erivedge royalty income has been relatively stable but not sufficient to fully offset Curis’ ongoing research and development and general operating costs, according to the company’s 2024 financial statements released on 03/12/2025, which noted that total revenue for 2024 remained modest compared with total operating expenses, as reported by Curis earnings release as of 03/12/2025.

From a pipeline perspective, the most closely watched asset has been emavusertib in hematologic cancers. Clinical development experienced a setback when the FDA placed a partial clinical hold on certain studies in 2022 after observing safety signals, a status that has continued to shape the risk profile of the program. Curis has worked with regulators to adjust protocols and dosing with the goal of addressing safety concerns while maintaining potential efficacy, according to development updates referenced in a company press release dated 06/28/2023 and reiterated in later corporate presentations, as summarized by Curis program update as of 06/28/2023.

Additional pipeline candidates include targeted therapies aimed at oncogenic pathways or epigenetic mechanisms that may be relevant both in hematologic malignancies and in solid tumors. These programs are at earlier stages of development, often preclinical or Phase 1, and therefore contribute more to the company’s long-term optionality than to near-term revenue. Curis emphasizes combination strategies and biomarker-driven patient selection, aligning with broader oncology trends where companies attempt to match specific molecular features to targeted agents. For US investors, understanding the stage of each asset, the size of the patient populations and the competitive landscape around similar mechanisms of action is critical for assessing potential future value, as outlined in pipeline charts shared by the company on 03/18/2025 and noted by Curis events overview as of 03/18/2025.

Conclusion

Curis remains a high-risk, high-uncertainty biotech story centered on a small portfolio of targeted oncology assets and a modest royalty stream from Erivedge. The ongoing impact of the FDA’s partial clinical hold on emavusertib and the company’s ability to generate compelling safety and efficacy data will likely be central drivers of sentiment toward the stock in the near term. For US investors, the Nasdaq listing offers direct exposure to early-stage oncology innovation but also to the funding and regulatory challenges typical for small biotechnology issuers. Careful monitoring of future regulatory updates, clinical results and financing actions may be important for understanding how the risk-reward profile of Curis evolves over time.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.